

France Cell Therapy Market Forecast 2022-2028

Market Report | 2022-10-24 | 120 pages | Inkwood Research

AVAILABLE LICENSES:

- Single User Price \$900.00
- Global Site License \$1000.00
- \$1200.00

Report description:

KEY FINDINGS

The France cell therapy market growth is expected to progress at a CAGR of 15.92% during the forecast period, 2022-2028. The France market growth prospects are attributed to the presence of leading research and biotech companies working in the cell therapies segment.

MARKET INSIGHTS

Europe is the second-largest gene and cell therapy market globally, with the UK and France in the top positions. France's biotech industry continues to contribute to the development of gene therapy and cell therapy fields, rendering it conducive to market competition with regard to cell therapies. For instance, Cell-Easy, a start-up in Toulouse specializing in stem cell therapy, collaborated with the University Hospital Centre in Toulouse, procuring the authorization to open a pharmaceutical manufacturing plant for the production of stem cells.

Further, biotechnology companies in France are increasingly prioritizing research activities in the central nervous system, infectious diseases, and oncology. Additionally, many France-based companies are engaged in expanding their businesses related to cell therapy. For instance, TreeFrog Therapeutics opened its first 1300 sq ft facility in June 2020 to scale up cell therapy manufacturing processes based on the induced pluripotent stem(iPS) in Bordeaux, France. As a result, the thriving biotechnology industry is propelling the France cell therapy market growth.

COMPETITIVE INSIGHTS

Some of the prominent firms in the market include Cellectis, TreeFrog Therapeutics, Bristol Myers Squibb Company, TheraVectys, Sangamo Therapeutics Inc, etc.

Our report offerings include:

- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents:

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY
 - 1.1. STUDY OBJECTIVES
 - 1.2. SCOPE OF STUDY
 - 1.3. METHODOLOGY
 - 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
 - 2.1. MARKET SIZE & ESTIMATES
 - 2.2. COUNTRY SNAPSHOT
 - 2.3. COUNTRY ANALYSIS
 - 2.4. KEY GROWTH ENABLERS
 - 2.5. KEY CHALLENGES
3. KEY ANALYTICS
 - 3.1. IMPACT OF COVID-19 ON CELL THERAPY MARKET
 - 3.2. PESTLE ANALYSIS
 - 3.2.1. POLITICAL
 - 3.2.2. ECONOMICAL
 - 3.2.3. SOCIAL
 - 3.2.4. TECHNOLOGICAL
 - 3.2.5. LEGAL
 - 3.2.6. ENVIRONMENTAL
 - 3.3. KEY MARKET TRENDS
 - 3.4. PORTER'S FIVE FORCES ANALYSIS
 - 3.4.1. BUYERS POWER
 - 3.4.2. SUPPLIERS POWER
 - 3.4.3. SUBSTITUTION
 - 3.4.4. NEW ENTRANTS
 - 3.4.5. INDUSTRY RIVALRY
 - 3.5. REGULATORY FRAMEWORK
 - 3.6. OPPORTUNITY MATRIX
4. MARKET BY CELL TYPE
 - 4.1. STEM CELL
 - 4.1.1. BONE MARROW
 - 4.1.2. BLOOD
 - 4.1.3. UMBILICAL CORD-DERIVED STEM CELL
 - 4.1.4. ADIPOSE-DERIVED STEM CELL
 - 4.1.5. OTHERS
 - 4.2. NON-STEM CELL
5. MARKET BY THERAPY TYPE
 - 5.1. AUTOLOGOUS
 - 5.2. ALLOGENEIC
6. MARKET BY THERAPEUTIC APPLICATION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1. MALIGNANCIES
- 6.2. MUSCULOSKELETAL DISORDERS
- 6.3. AUTOIMMUNE DISORDERS
- 6.4. DERMATOLOGY
- 6.5. OTHER APPLICATIONS
- 7. MARKET BY END-USER
 - 7.1. HOSPITALS & CLINICS
 - 7.2. ACADEMIC & RESEARCH INSTITUTES
- 8. COMPETITIVE LANDSCAPE
 - 8.1. KEY STRATEGIC DEVELOPMENTS
 - 8.1.1. MERGERS & ACQUISITIONS
 - 8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
 - 8.1.3. PARTNERSHIPS & AGREEMENTS
 - 8.1.4. BUSINESS EXPANSIONS
 - 8.2. COMPANY PROFILES
 - 8.2.1. BRISTOL MYERS SQUIBB COMPANY
 - 8.2.2. CELLECTIS
 - 8.2.3. SANGAMO THERAPEUTICS INC
 - 8.2.4. THERAVECTYS
 - 8.2.5. TREEFROG THERAPEUTICS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

France Cell Therapy Market Forecast 2022-2028

Market Report | 2022-10-24 | 120 pages | Inkwood Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$900.00
	Global Site License	\$1000.00
		\$1200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com